Women are increasingly keeping the use of GLP‑1 weight loss drugs like Wegovy hidden from their partners, a practice that raises medical and relational concerns.
Secret use of Wegovy emerges in personal stories
One Montreal resident, who asked to be identified only by her first name, began taking Wegovy after a telehealth doctor prescribed it without knowing her exact weight. Over six months she lost 30 pounds, dropping from 130 lb to what she calls her “healthy original weight” of 100 lb. When the medication was stopped, she regained 10 lb in a month, prompting her to restart at a maintenance dose.
She chose to keep the drug hidden from her boyfriend the second time she resumed it. She stores the refrigerated medication in the back of her fridge and, when traveling together, hides it in hotel or in‑law refrigerators. “It’s super awkward,” she says, describing the effort required to conceal the medication.
Related: Nia Long Back in the Spotlight
She hides it.
Her experience mirrors posts on the r/GLP1microdosing subreddit, where women share creative storage ideas—from tomato paste boxes to empty probiotic bottles—to avoid detection by partners.
Doctors observe the trend and note risks
Family and obesity specialist Kia Mitchell, MD in Jacksonville has encountered patients who hide GLP‑1s to avoid “debates at home.” She notes that secrecy can give patients a sense of control over the narrative of their weight loss, but it also carries potential drawbacks.
The practice of secrecy is not limited to romantic partners. Some women report hiding pills from teenage children or ex‑spouses to avoid unwanted questions or criticism.
Related: Plasma Replacement May Slow Aging Process
In practice, the hidden use of Wegovy can affect health outcomes. Unmonitored dosage adjustments may lead to suboptimal results or exacerbate side effects, and the stress of concealment itself can undermine the physiological benefits of the medication.
As the annual physical approaches, the Montreal woman worries that her doctor will notice the significant weight change without an explanation. She remains uncertain whether to disclose her ongoing Wegovy use, fearing both judgment and the potential impact on her treatment plan.
Medical professionals continue to observe the trend, noting that while telemedicine offers convenient access, it also creates gaps in overall care. The balance between privacy, partnership trends, and health outcomes remains a complex issue for women using GLP‑1 weight loss drugs.
